Cytokinetics, Inc. (Nasdaq: CYTK) has revealed its Vision 2025, titled "Leading with Science, Delivering for Patients," which sets forth the company's five-year key imperatives. These include achieving regulatory approvals for at least two drugs from its pipeline, building commercial capabilities to market and sell its medicines, generating sustainable and growing revenues from product sales, doubling its development pipeline to include ten therapeutic programs, expanding its discovery platform to muscle energetics, growth, and metabolism, and becoming a science-driven company people want to join and partner with.
Robert I. Blum, Cytokinetics’ President and Chief Executive Officer, emphasized the company's transformation over the past five years and its readiness to potentially bring forward at least two new medicines from its muscle biology-focused research. The company expects to deliver on the promise of its science, double its pipeline of novel mechanism drug candidates, and expand the breadth of its discovery platform.
For 2020, Cytokinetics has outlined several key milestones, particularly in its cardiac muscle programs. These include the second interim analysis of the GALACTIC-HF trial in Q1 2020, topline results from GALACTIC-HF in Q4 2020, completing enrollment in the METEORIC-HF trial, and conducting commercial readiness and developing a co-promotion plan in collaboration with Amgen. Additionally, the company plans to complete a Phase 1 SAD/MAD study of AMG 594, conduct the REDWOOD-HCM Phase 2 clinical trial of CK-274, and file an IND and initiate a Phase 1 study for CK-271.
In its skeletal muscle programs, Cytokinetics aims to engage with regulatory and reimbursement authorities in 2020 to prepare for a potential Phase 3 clinical trial and registration program for reldesemtiv in patients with ALS. The company also plans to advance CK-601 in IND-enabling studies and continue research activities directed to the cardiac and skeletal sarcomere and other muscle biology research programs, including collaboration with Astellas for the discovery of next-generation skeletal muscle activators.
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is collaborating with Amgen Inc. to develop omecamtiv mecarbil and with Astellas Pharma Inc. to develop reldesemtiv. Cytokinetics is also developing CK-274, a novel cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM).
